Decoy Therapeutics Provides Third Quarter 2026 Business Update
Key Highlights
- ➤$8.1 million cash balance at September 30, 2026, including $2.5 million restricted funding
- ➤Pan-coronavirus CTA/IND filing expected in 2H 2027 for Phase 1 trial
- ➤Optimized lead candidate showed potential for once-weekly dosing in preclinical studies
- ➤Pan-filovirus program targets Ebola, Marburg and related viruses
- ➤Decoy is pursuing non-dilutive funding and strategic collaborations across programs
Expert Statements
Rick Pierce, Chief Executive Officer of Decoy Therapeutics
“We are making excellent progress toward the clinic with our pan-coronavirus program, and our AI-enabled IMP³ACT™ platform continues to rapidly produce potential drug candidates against some of the world's deadliest viruses”
Rick Pierce, Chief Executive Officer of Decoy Therapeutics
“We are focused on advancing these programs efficiently, including leveraging non-dilutive funding from top-tier collaborators.”
Lead pan-coronavirus program expected to file CTA/IND in 2H 2027 Optimized lead candidate shows potential for once-weekly dosing in preclinical studies Cash on balance sheet of $8.1 million at September 30, 2026
CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs) to target major respiratory and high-consequence viral threats, today provided a business update for the third quarter ended September 30, 2026. During the quarter, Decoy advanced its lead pan-coronavirus program toward the clinic and identified an optimized lead candidate with potential for once-weekly dosing.
Get started
Create a free account to read the full story.